title: Antagonists of cholinergic and serotonergic responses of Aplysia buccal muscle.
abstract: Cholinergic and serotonergic receptors of Aplysia californica buccal muscles were characterized pharmacologically by determining compounds that effectively inhibited contractile responses to acetylcholine (ACh) and modulatory effects of serotonin (5-HT), respectively. pA50 for ACh to elicit contraction averaged 4.7 +/- 0.1 (mean +/- SE, equivalent to 2 x 10(-5) M). Both hexamethonium bromide and atropine inhibited ACh-elicited contractions, but neither inhibited the response completely, nor were the two together able to antagonize the response completely. Curare caused inhibition only at low ACh doses, and muscarinic antagonists pirenzapine and 4-diphenylacetoxy-N-methylpiperidine methiodide caused partial inhibition. The most effective blocker of ACh-elicited contractions was the nicotinic antagonist mecamylamine. 10(-4) M mecamylamine completely blocked the cholinergic response. ACh contractions were inhibited 90% within 10 min and took > 40 min to recover from mecamylamine. Specificity was indicated by the lack of effect of mecamylamine on potassium-elicited contraction. NAN-190 blocked the potentiating effect of 5-HT without having inhibitory or potentiating effects by itself on ACh-elicited contractions. NAN-190 blocked the potentiating effect of 8-OH-DPAT. Cholinergic receptors on Aplysia buccal muscles are most effectively inhibited by mecamylamine and may have mixed nicotinic/muscarinic character. Serotonergic receptors have pharmacological similarities to vertebrate 5-HT1A receptors and may be closely related to the gastropod 5-HTlym receptor.
authors.affiliation: Department of Physiology, Wayne State University, Detroit, MI 48201, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Ram
authors.forename: K
authors.initials: K
authors.lastname: Judge
authors.forename: M A
authors.initials: MA
authors.lastname: Jednak
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000109:Acetylcholine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000818:Animals; D001048:Aplysia / Q000502:physiology*; D001285:Atropine / Q000494:pharmacology; D018680:Cholinergic Antagonists / Q000494:pharmacology*; D018738:Hexamethonium / Q000494:pharmacology; D066298:In Vitro Techniques; D008464:Mecamylamine / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects* / Q000294:innervation; D010879:Piperazines / Q000494:pharmacology; D010890:Pirenzepine / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology*
chemical_list: D018680:Cholinergic Antagonists; D010879:Piperazines; D012702:Serotonin Antagonists; C058895:1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine; D018738:Hexamethonium; D010890:Pirenzepine; D008464:Mecamylamine; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D001285:Atropine; D000109:Acetylcholine